News

Keapstone Therapeutics is preparing to make the next steps in clinical candidate selection and first-in-human studies. This investment brings the total seed investment to € 2,4 million. Last year Parkinson’s UK together with Sheffield University launched the virtual biotech Keapstone Therapeutics to further develop compounds that boost the internal cellular defence mechanisms against oxidative stress to combat neurogenerative diseases. These compounds were discovered by IMI’s European Lead Factory. 

The European Lead Factory is remarkably attractive for SMEs. The consortium consists of 30 partners, of which 10 are SMEs. They perform the screening and help to translate innovative design ideas into industry‐standard compound libraries. ELF is also interacting with a high number of SMEs who have enrolled via the target crowdsourcing route with in total 25 programmes (out of 88 programmes in the portfolio).

On 16 and 17 April 2018 the European Lead Factory (ELF) Target Owner Workshop and Stakeholder Meeting took place in the heart of Europe, Brussels. An exciting row of speakers allowed for a retrospect on five years of successfully seeding and nursing innovative drug discovery projects. It also gave a hint about the future and how we can further grow the successful ELF platform to serve drug discovery for priority medicines.